These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28152225)

  • 1. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
    Sekine M; Kubuki Y; Kameda T; Takeuchi M; Toyama T; Kawano N; Maeda K; Sato S; Ishizaki J; Kawano H; Kamiunten A; Akizuki K; Tahira Y; Shimoda H; Shide K; Hidaka T; Kitanaka A; Yamashita K; Matsuoka H; Shimoda K
    Eur J Haematol; 2017 May; 98(5):501-507. PubMed ID: 28152225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis.
    Satake A; Konishi A; Azuma Y; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Fujita S; Nakaya A; Ito T; Ishii K; Nomura S
    Eur J Haematol; 2020 Dec; 105(6):704-711. PubMed ID: 32564395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma.
    Ishitsuka K; Yurimoto S; Tsuji Y; Iwabuchi M; Takahashi T; Tobinai K
    Eur J Haematol; 2019 May; 102(5):407-415. PubMed ID: 30740787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
    Ureshino H; Kamachi K; Kimura S
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies.
    Ishida T; Utsunomiya A; Jo T; Yamamoto K; Kato K; Yoshida S; Takemoto S; Suzushima H; Kobayashi Y; Imaizumi Y; Yoshimura K; Kawamura K; Takahashi T; Tobinai K; Ueda R
    Cancer Sci; 2017 Oct; 108(10):2022-2029. PubMed ID: 28776876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
    Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
    J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Impact of a Humanized CCR4 Antibody (Mogamulizumab) in 14 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated at a Single Institution During a Three-year Period (2012-2014).
    Kawano N; Kuriyama T; Sonoda KH; Yoshida S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
    Intern Med; 2016; 55(11):1439-45. PubMed ID: 27250049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of mogamulizumab and establishment of an optimal therapy based on genomic biomarkers: from the academic viewpoint].
    Iida S; Ishida T; Ueda R
    Yakugaku Zasshi; 2015; 135(5):663-9. PubMed ID: 25948299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
    Winsett FT; Lewis DJ; Duvic M
    Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mogamulizumab
    Phillips AA; Fields PA; Hermine O; Ramos JC; Beltran BE; Pereira J; Wandroo F; Feldman T; Taylor GP; Sawas A; Humphrey J; Kurman M; Moriya J; Dwyer K; Leoni M; Conlon K; Cook L; Gonsky J; Horwitz SM;
    Haematologica; 2019 May; 104(5):993-1003. PubMed ID: 30573506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of post-mogamulizumab relapse of acute-type adult T-cell leukemia/lymphoma successfully treated with mogamulizumab and etoposide.
    Sekiguchi Y; Shimada A; Ichikawa K; Wakabayashi M; Sugimoto K; Kinoshita A; Suga Y; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
    Int J Clin Exp Pathol; 2014; 7(9):6278-90. PubMed ID: 25337281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.
    Fuji S; Inoue Y; Utsunomiya A; Moriuchi Y; Uchimaru K; Choi I; Otsuka E; Henzan H; Kato K; Tomoyose T; Yamamoto H; Kurosawa S; Matsuoka K; Yamaguchi T; Fukuda T
    J Clin Oncol; 2016 Oct; 34(28):3426-33. PubMed ID: 27507878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mogamulizumab Plus EPOCH Therapy for Patients With Newly Diagnosed Aggressive Adult T-cell Leukemia/lymphoma.
    Jo T; Matsuzaka K; Shioya H; Tominaga H; Sakai T; Kaneko Y; Hayashi S; Matsuo M; Taguchi J; Abe K; Shigematsu K; Kubota-Koketsu R
    Anticancer Res; 2020 Sep; 40(9):5237-5243. PubMed ID: 32878812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.
    Ishida T; Jo T; Takemoto S; Suzushima H; Uozumi K; Yamamoto K; Uike N; Saburi Y; Nosaka K; Utsunomiya A; Tobinai K; Fujiwara H; Ishitsuka K; Yoshida S; Taira N; Moriuchi Y; Imada K; Miyamoto T; Akinaga S; Tomonaga M; Ueda R
    Br J Haematol; 2015 Jun; 169(5):672-82. PubMed ID: 25733162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
    Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
    Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
    [No Abstract]   [Full Text] [Related]  

  • 16. Ascites Retention during Mogamulizumab Treatment in a Patient with Adult T-cell Leukemia/lymphoma.
    Shima T; Kamezaki K; Higashioka K; Takashima S; Yoshimoto G; Kato K; Muta T; Takenaka K; Iwasaki H; Miyamoto T; Akashi K
    Intern Med; 2016; 55(13):1793-6. PubMed ID: 27374686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.
    Ureshino H; Kusaba K; Kidoguchi K; Sano H; Nishioka A; Itamura H; Yoshimura M; Yokoo M; Shindo T; Kubota Y; Ando T; Kojima K; Sueoka E; Kimura S
    Ann Hematol; 2019 Feb; 98(2):465-471. PubMed ID: 30264165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T-Cell Leukemia/Lymphoma.
    Iyama S; Sato T; Ohnishi H; Kanisawa Y; Ohta S; Kondo T; Mori A; Tsutsumi Y; Kuroda H; Kakinoki Y; Yamamoto S; Takahashi T; Shindo M; Torimoto Y; Sato K; Iwasaki H; Haseyama Y; Kohda K; Nagamachi Y; Hirayama Y; Sakai H; Hirata Y; Fukuhara T; Ikeda H; Kobune M; Kato J; Kurosawa M
    Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):23-30.e2. PubMed ID: 27727135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL).
    Ceesay MM; Matutes E; Taylor GP; Fields P; Cavenagh J; Simpson S; Ho A; Devereux S; Mufti GJ; Pagliuca A
    Leuk Res; 2012 Jul; 36(7):857-61. PubMed ID: 22209076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma.
    Nakashima J; Imaizumi Y; Taniguchi H; Ando K; Iwanaga M; Itonaga H; Sato S; Sawayama Y; Hata T; Yoshida S; Moriuchi Y; Miyazaki Y
    Int J Hematol; 2018 Nov; 108(5):516-523. PubMed ID: 30032392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.